Flag of the European Union EU Clinical Trials Register Help

Clinical trials for masitinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: masitinib. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Ongoing) SE (Restarted) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) PL (Ongoing) IE (Temporarily Halted) IT (Restarted) NO (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002293-41 Sponsor Protocol Number: AB12005 Start Date*: 2015-07-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to g...
    Medical condition: Non resectable locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) BE (Completed) DE (Prohibited by CA) SK (Prohibited by CA) GR (Ongoing) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2011-001790-41 Sponsor Protocol Number: AB11002 Start Date*: 2013-04-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti...
    Medical condition: Gastrointestinal stromal tumor resistant to imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000639-30 Sponsor Protocol Number: AB20009 Start Date*: 2022-01-12
    Sponsor Name:AB Science
    Full Title: A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the T...
    Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) DE (Ongoing) GR (Ongoing) BG (Ongoing) NO (Temporarily Halted) PT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003735-32 Sponsor Protocol Number: AB11005 Start Date*: 2015-04-01
    Sponsor Name:AB Science
    Full Title: A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w...
    Medical condition: Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prohibited by CA) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001635-27 Sponsor Protocol Number: AB20001 Start Date*: 2020-05-04
    Sponsor Name:AB Science
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients ...
    Medical condition: Hospitalized Moderate and Severe COVID-19 Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000972-25 Sponsor Protocol Number: AB06006 Start Date*: 2013-06-06
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety ...
    Medical condition: Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicaps
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026891 Mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Prohibited by CA) GB (Completed) IT (Completed) BG (Completed) HU (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024423-24 Sponsor Protocol Number: AB10015 Start Date*: 2013-01-29
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients su...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) SK (Prohibited by CA) IT (Completed) HU (Completed) PT (Completed) IE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000493-30 Sponsor Protocol Number: AB12010 Start Date*: 2015-03-03
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fl...
    Medical condition: Metastatic colorectal cancer after 2 or 3 previous lines of treatment
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SK (Prohibited by CA) CZ (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018982-43 Sponsor Protocol Number: AB08025 Start Date*: 2010-06-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbaz...
    Medical condition: Mélanome métastasé ou non-opérable stade 3 ou stade 4, ne portant pas de mutation dans le domaine juxta-membranaire de c-kit
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000974-18 Sponsor Protocol Number: AB07012 Start Date*: 2009-05-06
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabin...
    Medical condition: advanced/metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003740-23 Sponsor Protocol Number: AB13004 Start Date*: 2015-02-04
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patien...
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000809-23 Sponsor Protocol Number: AB12003 Start Date*: 2014-10-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo i...
    Medical condition: metastatic Castrate Resistant Prostate Cancer (mCRPC).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Restarted) SK (Prohibited by CA) GR (Completed) CZ (Ongoing) GB (Temporarily Halted) IT (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2021-005406-96 Sponsor Protocol Number: AB20006 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with sev...
    Medical condition: severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10075217 Mast cell activation syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) BE (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004162-34 Sponsor Protocol Number: AB12004 Start Date*: 2015-01-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with l...
    Medical condition: stromal gastrointestinal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) CZ (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000973-40 Sponsor Protocol Number: AB04030 Start Date*: 2008-12-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in...
    Medical condition: gastro-intestinal stromal tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Ongoing) DE (Prohibited by CA) AT (Ongoing) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020603-79 Sponsor Protocol Number: AB08004 Start Date*: 2012-12-21
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, randomized, double-blind, placebo-controlled, 2-parallel groups, phase 2 study to evaluate efficacy and safety of 12 weeks treatment with masitinib versus placebo in pat...
    Medical condition: patients suffering from Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-000897-36 Sponsor Protocol Number: AB14005 Start Date*: 2016-04-26
    Sponsor Name:AB science
    Full Title: A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric ...
    Medical condition: Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10017776 Gastric carcinoma stage III LLT
    18.1 100000004864 10017777 Gastric carcinoma stage IV NOS LLT
    18.1 100000004864 10017778 Gastric carcinoma stage IV without metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-024424-26 Sponsor Protocol Number: AB10013 Start Date*: 2015-05-05
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associ...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prohibited by CA)
    Trial results: View results
    EudraCT Number: 2009-017930-35 Sponsor Protocol Number: AB06002 Start Date*: 2010-06-29
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and ...
    Medical condition: Multiple Myeloma relapsing after one previous line therapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) AT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) ES (Completed) IT (Ongoing) GR (Completed) HU (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 20:25:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA